Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04040 (Catalase)
 3,577 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Catalase is known to map at chromosome 11p13. It is one of the closest known markers to the WAGR locus. Restriction fragment length polymorphisms (RFLP) of the catalase gene may be invaluable for studying rearrangements in somatic tumours, linkage in cases of familial Wilms tumour, and the relationship between sporadic and familial aniridia. We describe a catalase RFLP with two different enzymes and use these polymorphisms to exclude deletion of the catalase gene in patients with sporadic aniridia, including one who is known to have a deletion and another suspected of having a deletion.
 ...
PMID:Use of catalase polymorphisms in the study of sporadic aniridia. 301 56

We report the isolation and sequence of partial cDNA clones coding for human catalase. These clones were recovered from a human fibroblast cDNA library by screening with mixtures of oligonucleotide probes deduced from the amino acid sequence of human erythrocyte catalase. A comparison of their nucleotide sequence with the known protein sequence and mapping of homologous DNA sequences to the short arm of chromosome 11 in somatic cell hybrids confirmed that they coded for catalase. One of these clones contained a 462-base insertion interrupting the coding sequence with stop codons in all three reading frames. The 5' and 3' ends of the insertion correspond to the donor and acceptor consensus sequences of introns. Inspection of clones lacking the insertion confirm the location of the splice sites. We suggest this clone corresponds to the product of reverse transcription of an unspliced mRNA species. The catalase gene is the closest genetic marker mapped to Wilms tumor, one of the most prevalent of childhood cancers. Catalase cDNA probes will be useful to the examination of mitotic recombination in the etiology of this disease and may provide a useful starting point to the search for the putative Wilms tumor gene.
 ...
PMID:Isolation of human fibroblast catalase cDNA clones. Sequence of clones derived from spliced and unspliced mRNA. 654 44

Two unrelated patients with clinical features of 11p13 deletion syndrome, 3 years old and 3 months old, are reported. The clinical features of the patients included mental retardation, aniridia, nystagmus, blepharophimosis, and genitourinary abnormalities. Both patients were apparently free from Wilms' tumor and gonadoblastoma. Prometaphase banding analyses revealed a 46,XY,del(11)(p1300p1500) karyotype in one patient and 46,XX,dir ins(11;2)(p13;q12q23) in the other. Catalase activities in the erythrocytes in the two patients were respectively 65% and 56% of those of normal controls, close to the expected values in hemizygosity of the catalase gene. These findings confirmed a close linkage of the gene for catalase and those for the aniridia--Wilm's tumor or gonadoblastoma complex.
 ...
PMID:Chromosome abnormalities involving 11p13 and low erythrocyte catalase activity. 710 75

Previous studies in our laboratory have shown that the elevation of reactive oxygen species levels and the repression of the antioxidant enzyme, catalase, played a critical role in the in vitro progression of benign papilloma cells to malignant carcinoma cells. Catalase message, protein levels, and activity levels were found to be downregulated in the malignantly progressed cells. The goal of this study is to further characterize the repression of catalase in malignant progression of mouse skin tumors. To validate the in vitro observations, we examined catalase expression in tumor samples generated by the multistep chemical carcinogenesis protocol. Higher levels of catalase mRNA and protein were observed in benign papillomas versus malignant carcinomas. Nuclear run-on analysis showed that catalase repression in the cultured malignant cells was transcription-dependent. Results from luciferase reporter assays indicated that malignant cells have lower catalase promoter activities than benign papilloma cells, in part through the Wilm's tumor suppressor 1 (WT1) binding site within the proximal promoter region. The WT1 protein levels were found to be inversely correlated with the observed catalase promoter activities, with higher levels observed in the malignant cells versus the benign cells. These results led us to conclude that WT1 is acting as a transcription repressor in catalase gene regulation during tumor progression.
 ...
PMID:Transcriptional repression of catalase in mouse skin tumor progression. 1554 52